Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NC › Greensboro › NPI 1346233277
Lab

Solstas Lab Partners Group LLC

Solstas Lab Partners Group LLC was paid $11.62M by Medicaid between Jan 2018 and Jul 2019, across 350 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 6.1% of everything it billed.

33Billing provider infoSOLSTAS LAB PARTNERS GROUP LLC
GREENSBORO, NC 27410
33aNPI1346233277assigned 08/25/2005
33bProvider typeClinical Medical Laboratory
28Total paid$11.62M
24GClaims1,232,218
24DCodes billed350
24AFirst – last monthJan 2018 – Jul 2019
Compared with peers

Next to other Clinical Medical Laboratory providers in North Carolina

Rank by total paid#15 of 128
Median peer was paid$268K
This provider vs. median43×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$500K$1.0M$1.5M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018880,843$7.98M
2019351,375$3.64M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 6.1% 32,767 28,837 $709K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 6.0% 32,355 28,487 $696K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 5.3% 30,984 27,927 $614K
80061 Lipid panel 5.2% 69,225 62,995 $600K
84443 Thyroid stimulating hormone (TSH) 4.6% 51,385 47,192 $540K
80053 Comprehensive metabolic panel 4.1% 88,908 79,555 $482K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 3.4% 19,772 17,486 $391K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 3.0% 69,660 61,170 $343K
86003 2.9% 5,027 3,752 $339K
83036 Hemoglobin; glycosylated (A1C) 2.6% 47,977 43,653 $300K
87086 Culture, bacterial; quantitative colony count, urine 2.3% 42,726 38,444 $266K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 2.2% 12,292 10,093 $254K
338 more codes
80050 General health panel 2.0% 22,107 $229K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2.0% 6,678 $228K
86480 1.5% 4,814 $175K
80074 1.3% 5,508 $146K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 1.2% 823 $145K
84439 1.2% 21,038 $139K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.2% 7,746 $136K
87081 1.1% 23,270 $130K
87088 1.1% 20,145 $127K
82607 1.0% 12,889 $119K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 5,378 $103K
86803 <1% 9,711 $97K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 3,022 $94K
87070 <1% 11,940 $92K
80055 <1% 3,703 $90K
85027 <1% 24,255 $90K
87186 <1% 14,128 $88K
82728 <1% 9,116 $84K
80048 Basic metabolic panel (calcium, ionized) <1% 21,607 $82K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 3,404 $78K
88142 <1% 4,653 $76K
86787 <1% 5,583 $72K
86336 <1% 1,537 $71K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 264 $68K
87660 <1% 4,099 $67K
86235 <1% 1,314 $66K
82746 <1% 6,726 $65K
84481 <1% 4,715 $65K
87077 <1% 10,612 $62K
83013 <1% 1,150 $61K
87510 <1% 4,106 $60K
86850 <1% 5,282 $58K
83970 <1% 3,536 $57K
84153 <1% 4,976 $54K
86360 <1% 1,760 $54K
80081 <1% 1,455 $53K
84146 <1% 3,177 $51K
84436 <1% 12,745 $49K
86592 <1% 13,876 $48K
86008 <1% 646 $47K
83550 <1% 8,569 $46K
84479 <1% 10,666 $44K
84702 <1% 5,538 $42K
83540 <1% 10,095 $42K
87150 <1% 1,656 $42K
86696 <1% 3,253 $41K
86038 <1% 5,247 $40K
82105 <1% 3,143 $40K
87799 <1% 856 $40K
87340 <1% 5,183 $39K
82785 <1% 2,504 $38K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 871 $38K
APT16 <1% 2,823 $38K
84403 <1% 2,225 $37K
83001 <1% 2,549 $37K
83880 <1% 2,719 $37K
82677 <1% 1,651 $36K
86361 <1% 2,971 $36K
82570 <1% 11,966 $34K
80164 <1% 4,140 $33K
87902 <1% 320 $32K
83718 <1% 3,190 $32K
83002 <1% 2,078 $31K
87147 <1% 6,303 $31K
83516 <1% 3,945 $30K
82043 <1% 9,635 $30K
83525 <1% 2,716 $29K
80076 <1% 5,185 $29K
86140 <1% 7,627 $28K
87522 Neg quan hep c or qual rna <1% 1,729 $28K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 717 $28K
83735 <1% 7,503 $27K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,218 $27K
82784 <1% 2,808 $26K
82670 <1% 1,411 $26K
83655 <1% 2,710 $24K
87650 <1% 1,332 $23K
86762 <1% 1,890 $23K
86665 <1% 1,953 $23K
86695 <1% 2,635 $22K
86376 <1% 2,090 $21K
87209 <1% 1,361 $20K
85652 <1% 9,683 $20K
87480 <1% 4,101 $19K
36415 Collection of venous blood by venipuncture <1% 53,753 $17K
86160 <1% 1,189 $17K
81001 <1% 8,774 $17K
83690 <1% 3,551 $16K
88141 <1% 4,288 $16K
84550 <1% 6,927 $16K
86664 <1% 1,282 $16K
86147 <1% 695 $16K
86431 <1% 4,152 $16K
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel <1% 36 $15K
84144 <1% 1,072 $15K
84480 <1% 2,139 $15K
87512 <1% 594 $15K
82950 <1% 3,399 $14K
86706 <1% 2,229 $14K
86800 <1% 1,204 $14K
85610 <1% 7,552 $14K
87046 <1% 1,915 $14K
87427 <1% 1,444 $14K
86901 <1% 4,393 $13K
86900 <1% 4,391 $13K
87205 <1% 4,005 $13K
86200 <1% 1,720 $13K
86225 <1% 1,487 $12K
82248 <1% 4,756 $12K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 184 $12K
82150 <1% 2,659 $12K
87045 <1% 1,730 $11K
82627 <1% 670 $11K
85660 <1% 1,943 $11K
80348 <1% 1,486 $11K
87075 <1% 1,514 $11K
87177 <1% 1,671 $11K
86704 <1% 1,828 $11K
82951 <1% 959 $10K
86708 <1% 1,211 $10K
84270 <1% 675 $10K
80069 <1% 3,267 $10K
83021 <1% 680 $10K
82140 <1% 1,228 $10K
86618 <1% 782 $9K
87536 <1% 288 $9K
82550 <1% 2,189 $9K
87255 <1% 403 $9K
82274 <1% 855 $9K
84156 <1% 4,326 $9K
83630 <1% 644 $8K
86355 <1% 450 $8K
86039 <1% 1,200 $8K
80185 <1% 1,208 $8K
82533 <1% 657 $7K
80178 <1% 1,584 $7K
87449 <1% 1,157 $7K
84681 <1% 609 $7K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 186 $7K
87324 <1% 1,132 $7K
86357 <1% 396 $7K
86359 <1% 497 $7K
85045 <1% 2,331 $7K
87338 <1% 763 $7K
82977 <1% 1,426 $7K
86146 <1% 216 $6K
83520 <1% 845 $6K
82947 <1% 2,330 $6K
87631 <1% 75 $6K
86317 <1% 626 $6K
84703 <1% 1,040 $6K
86021 <1% 933 $6K
86141 <1% 900 $6K
85379 <1% 885 $6K
83615 <1% 1,439 $5K
84154 <1% 440 $5K
86757 <1% 414 $5K
86255 <1% 582 $5K
85060 <1% 461 $5K
80156 <1% 765 $5K
84100 <1% 3,109 $5K
81025 <1% 651 $5K
82565 <1% 1,762 $4K
82247 <1% 1,233 $4K
86780 <1% 459 $4K
85730 <1% 1,261 $4K
86777 <1% 357 $4K
82378 <1% 413 $4K
87493 <1% 224 $4K
84466 <1% 588 $4K
86778 <1% 273 $4K
82465 <1% 1,016 $4K
86334 <1% 350 $4K
87329 <1% 413 $4K
87899 <1% 537 $4K
84450 <1% 1,662 $3K
80346 <1% 310 $3K
83090 <1% 417 $3K
85018 <1% 2,393 $3K
84165 <1% 497 $3K
82952 <1% 930 $3K
84484 <1% 454 $3K
87040 <1% 439 $3K
84402 <1% 228 $3K
84432 <1% 206 $3K
86705 <1% 521 $3K
88112 <1% 88 $3K
83721 <1% 689 $3K
81003 <1% 2,070 $2K
84134 <1% 344 $2K
80361 <1% 252 $2K
82652 <1% 201 $2K
80197 <1% 544 $2K
83704 <1% 286 $2K
83883 <1% 315 $2K
APT15 <1% 211 $2K
87481 <1% 171 $2K
88342 <1% 133 $2K
80202 <1% 316 $2K
86304 <1% 198 $2K
86644 <1% 193 $2K
86663 <1% 202 $2K
86645 <1% 173 $2K
82310 <1% 1,356 $2K
85014 <1% 1,507 $2K
80349 <1% 234 $2K
86735 <1% 214 $2K
83631 <1% 127 $2K
88312 <1% 39 $2K
84460 <1% 1,787 $2K
80177 <1% 352 $2K
0001M <1% 136 $2K
87807 <1% 131 $2K
80324 <1% 212 $2K
81015 <1% 604 $2K
81511 <1% 121 $2K
84520 <1% 593 $2K
86765 <1% 199 $1K
86870 <1% 61 $1K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 63 $1K
86308 <1% 334 $1K
82040 <1% 686 $1K
83010 <1% 218 $1K
82955 <1% 301 $1K
82330 <1% 216 $1K
80162 <1% 349 $1K
82610 <1% 502 $1K
86812 <1% 55 $1K
88341 <1% 40 $1K
86709 <1% 175 $1K
82747 <1% 110 $1K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 181 $1K
83698 <1% 277 $1K
84163 <1% 107 $1K
84132 <1% 590 $1K
80051 <1% 204 $1K
86593 <1% 274 $1K
88304 <1% 61 $1K
82172 <1% 320 $1K
81241 <1% 44 $997.75
84425 <1% 162 $944.53
80175 <1% 126 $940.47
83921 <1% 103 $857.80
84166 <1% 87 $849.42
87210 <1% 298 $835.58
82164 <1% 85 $834.30
84155 <1% 574 $829.15
86300 <1% 108 $812.99
83695 <1% 336 $801.90
82103 <1% 121 $779.88
80365 <1% 102 $748.65
82024 <1% 32 $686.91
84445 <1% 42 $644.03
81374 <1% 17 $616.72
86738 <1% 68 $598.35
84478 <1% 212 $593.10
82390 <1% 115 $577.79
86301 <1% 44 $542.38
87486 <1% 32 $495.84
87581 <1% 32 $495.84
86617 <1% 73 $495.63
83519 <1% 45 $490.09
87015 <1% 222 $457.75
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 911 $451.41
80184 <1% 86 $449.82
84305 <1% 36 $439.35
80159 <1% 42 $413.85
84075 <1% 408 $413.71
85613 <1% 70 $406.29
85041 <1% 255 $371.13
86886 <1% 57 $304.01
81240 <1% 15 $302.86
82553 <1% 41 $288.51
80353 <1% 73 $273.69
87625 <1% 14 $264.05
89055 <1% 72 $247.46
87140 <1% 38 $243.46
81000 <1% 885 $240.90
87185 <1% 65 $232.12
82672 <1% 19 $228.94
85048 <1% 111 $217.31
85004 <1% 353 $204.22
84295 <1% 147 $198.23
85651 <1% 64 $197.42
87328 <1% 27 $197.30
87272 <1% 14 $186.44
85240 <1% 15 $186.01
84300 <1% 51 $171.49
82525 <1% 26 $170.27
85007 <1% 81 $157.40
80356 <1% 33 $147.23
82239 <1% 13 $142.40
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 134 $137.07
36416 <1% 784 $136.85
87425 <1% 15 $128.22
83935 <1% 28 $127.60
80373 <1% 32 $124.32
80320 <1% 32 $121.18
80360 <1% 31 $116.41
80372 <1% 30 $112.97
80354 <1% 30 $112.97
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 110 $112.70
85300 <1% 14 $109.85
82340 <1% 27 $107.54
80345 <1% 32 $97.14
86707 <1% 13 $92.06
80323 <1% 30 $88.02
87206 <1% 48 $87.25
84630 <1% 15 $85.23
80358 <1% 35 $85.07
80357 <1% 29 $83.99
80368 <1% 29 $83.99
80359 <1% 29 $83.99
80366 <1% 29 $83.99
80355 <1% 29 $83.99
80321 <1% 29 $83.99
80367 <1% 29 $83.90
80377 <1% 31 $83.90
80364 <1% 29 $83.90
80333 <1% 29 $83.72
80370 <1% 29 $81.39
80337 <1% 30 $80.39
80326 <1% 29 $79.55
82575 <1% 18 $75.10
80338 <1% 30 $72.56
80344 <1% 30 $72.56
80299 <1% 14 $71.98
82104 <1% 14 $64.10
86001 <1% 13 $53.01
85046 <1% 14 $47.12
83992 <1% 34 $43.82
80330 <1% 29 $28.79
80340 <1% 30 $24.92
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 90 $20.75
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 77 $3.55
82435 0% 12 $0.00
G0475 Hiv antigen/antibody, combination assay, screening 0% 14 $0.00
87999 0% 29 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBOWLES, CHARLES (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under BOWLES, CHARLES

Full network →
ProviderLocationPaid
Quest Diagnostics LLCMarlborough, MA$209.74M
Quest Diagnostics of Pennsylvania, INC.Pittsburgh, PA$132.39M
Quest Diagnostics Clinical Laboratories INCSeattle, WA$109.23M
Quest Diagnostics Clinical Laboratories INCPortland, OR$21.85M
Quest Diagnostics of Pennsylvania INC.Buffalo, NY$20.20M
Quest Diagnostics Clinical Laboratories INCCollegeville, PA$12.52M
Quest Diagnostics Incorporated MiFlint, MI$8.64M
Quest Diagnostics Clinical Laboratories INCTucker, GA$3.66M
Unilab CorporationWest Hills, CA$3.12M
Quest Diagnostics of Pennsylvania INC.Twinsburg, OH$2.56M
Quest Diagnostics Incorporated MDFalls Church, VA$936K
Quest Diagnostics LLCWallingford, CT$706K
Quest Diagnostics of Pennsylvania INC.North Syracuse, NY$492K
Solstas Lab Partners, LLCKnoxville, TN$455K
Quest Diagnostics Clinical Laboratories INCNorristown, PA$319K
Unilab CorporationSan Jose, CA$253K
Unilab CorporationOrange, CA$122K
Quest Diagnostics LLCStratford, CT$103K
Unilab CorporationBakersfield, CA$53K
Quest Diagnostics Clinical Laboratories INCHorsham, PA$48K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.